A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer

NCT00140140 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

16

Enrollment

INDUSTRY

Sponsor class

Stopped Unable to determine the optimum tolerated dose

Conditions

Stage IV (Metastatic) Breast Cancer

Interventions

DRUG: ABI-007
DRUG: vinorelbine
DRUG: Trastuzumab
BIOLOGICAL: G-CSF

Sponsor

Celgene